Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome

American Heart Journal

Volumn 148, Issue 3, 2004, Pages 439-446

  Kassem Moussa, Hassan ^a   Mahaffey, Kenneth W ^a   Graffagnino, Carmelo ^a   Tasissa, Gudaye ^a   Sila, Cathy A ^b   Simes, R John ^c   White, Harvey D ^d   Califf, Robert M ^a   Bhapkar, Manjshri V ^a   Newby, L Kristin ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; SIBRAFIBAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DEATH; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIMES; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS;

EID: 4644280096     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.01.028     Document Type: Article

References (30)

1. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
2. GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 337:1997;1118-1123
3. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782
4. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 337:1997;447-452
5. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation. 97:1998;2386-2395
6. Cannon C.P., McCabe C.H., Wilcox R.G., et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 102:2000;149-156
7. Mahaffey K.W., Harrington R.A., Simoons M.L., et al. for the PURSUIT Investigators. Stroke in patients with acute coronary syndromes incidence and outcomes in the Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation. 99:1999;2371-2377
8. Newby L.K., Ohman E.M., Christenson R.H., et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status the paragon-B troponin T substudy. Circulation. 103:2001;2891-2896
9. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes a randomised trial: Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 355:2000;337-345
10. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation. 103:2001;1727-1733
11. Newby L.K. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial: Symphony Steering Committee. Am Heart J. 138:1999;210-218
12. Taylor T.N., Davis P.H., Torner J.C. Lifetime cost of stroke in the United States. Stroke. 27:1996;1459-1466
13. Cronin L., Mehta S.R., Zhao F., et al. Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome a study involving >18 000 patients. Circulation. 104:2001;269-274
14. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomized trials of >1000 patients. Lancet. 343:1994;311-322
15. Komrad M.S., Coffey C.E., Coffey K.S., et al. Myocardial infarction and stroke. Neurology. 34:1984;1403-1409
16. Segal A.Z., Abernethy W.B., Palacios I.F., et al. Stroke as a complication of cardiac catheterization risk factors and clinical features. Neurology. 56:2001;975-977
17. Stamou S.C., Hill P.C., Dangas G., et al. Stroke after coronary artery bypass incidence, predictors, and clinical outcome. Stroke. 32:2001;1508-1513
18. Morgenstern L.B., Pandey D.K., Smith M.A., et al. Greater stroke rate during hospitalization for acute heart disease among Mexican Americans than non-Hispanic whites. Neuroepidemiology. 18:1999;241-247
19. Ault K.A., Cannon C.P., Mitchell J., et al. Platelet activation in patients after an acute coronary syndrome results from the TIMI-12 trial: Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 33:1999;634-639
20. Merlini P.A., Bauer K.A., Oltrona L., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68
21. Tegos T.J., Kalodiki E., Daskalopoulou S.S., et al. Stroke epidemiology, clinical picture, and risk factors, part I of III. Angiology. 51:2000;793-808
22. Kramer J.M., Newby L.K., Chang W., et al. International variation in the use of evidence-based medicines for acute coronary syndromes. Eur Heart J. 24:2003;2133-2144
23. McCloskey L.W., Psaty B.M., Koepsell T.D., et al. Level of blood pressure and risk of myocardial infarction among treated hypertensive patients. Arch Intern Med. 152:1992;513-520
24. Irie K., Yamaguchi T., Minematsu K., et al. The J-curve phenomenon in stroke recurrence. Stroke. 24:1993;1844-1849
25. MacMahon S., Rodgers A., Neal B., et al. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension. 29:1997;537-538
26. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 285:2001;1711-1718
27. White H.D., Simes R.J., Anderson N.E. Impact of pravastatin therapy on the risk of stroke results from the LIPID Study. N Engl J Med. 343:2000;317-326
28. Chalmers J.P. Ongoing trials of angiotensin-converting enzyme inhibition what they can tell us. Am J Hypertens. 14:2001;270S-275S
29. Derdeyn C.P. Diffusion-weighted imaging as a surrogate marker for stroke as a complication of cerebrovascular procedures and devices. Am J Neuroradiol. 22:2001;1234-1235
30. Masuda J., Nabika T., Notsu Y. Silent stroke pathogenesis, genetic factors and clinical implications as a risk factor. Curr Opin Neurol. 14:2001;77-82